For the past three years' measurement of amniotic fluid microvillar enzyme activities has been used for prospective second trimester prenatal diagnosis of cystic fibrosis (CF). Most mothers with abnormally low enzyme activities signalling an affected fetus have chosen termination of pregnancy. It is possible to confirm the diagnosis of CF in the fetus by analysis of the biochemistry of the fetal meconium,2 3 but hitherto there has been no independent way of verifying that abnormal fetal meconium correctly indicates a CF fetus.
The discovery of restriction fragment length polymorphisms (RFLPs) tightly linked to the CF gene4 5 has now made first trimester prenatal diagnosis of CF possible.6 Since recombination between the DNA markers (pJ3. 11, met H, and met D) and the CF gene is very rare,7 such diagnoses have high predictive accuracy. We have therefore used DNA typing on fetal tissue in an attempt to confirm diagnoses originally based on microvillar enzyme testing. Such typing also permits a subsequent first trimester prenatal diagnosis to be made even when a couple has no living affected child.
Materials and methods
At the start of this study it was anticipated that some of the microvillar enzyme based diagnoses might turn out to be false positives. Blood samples were therefore only requested from those couples who were contemplating further pregnancies and who would benefit from knowing whether they were informative for DNA based prenatal diagnosis. The criteria for inclusion of the seven families in the study were: (1) fetal tissues had been conserved from a second trimester fetus, (2) The primary objective of this study was to investigate whether DNA typing of fetal tissues from a second trimester abortus could be used to confirm a diagnosis of CF which was originally based on amniotic fluid microvillar enzyme activities. DNA typing depends on the analysis of RFLPs cosegregating with the CF gene, and it is therefore usually necessary to have blood samples from the father, the mother, and an index affected child in order to establish the phase relationships of the markers. It is estimated that in about 80% of families the use of the probes pJ3-11, met H, and met D will allow a diagnosis of CF to be made. 6 We have been able to acquire the appropriate blood samples from seven families where one or more second trimester terminations of pregnancy had been carried out. In all of these, the band patterns of father, mother, and index affected child were fully informative, and therefore the unique genotype of the index affected child should have been repeated in the abortus tissues.
Adequate extracts of undegraded DNA were obtained from all eight sets of fetal tissues. This is surprising in view of the fact that a majority of samples extracted were small intestine, a tissue thought to be prone to autolytic degradation. All the samples had been stored frozen for long periods of time (up to three years), and in no case had any special precautions been taken to preserve the DNA. Tissues were not frozen until several hours after expulsion of the fetus and were then kept at -20°C rather than at lower temperatures. This suggests that such tissue DNA is relatively stable and that the methods for confirmation of diagnosis described here can be used on other frozen samples.
In all eight sets of fetal tissue the microvillar enzyme based diagnosis of CF was confirmed by DNA typing.
For many couples seeking prenatal diagnosis of CF, the early death of an index affected child precludes the use of DNA markers on a first trimester chorionic villus sample (CVS). Such couples may opt for second trimester amniocentesis and microvillar enzyme diagnosis. If the fetus is deemed to be affected and termination of pregnancy carried out, DNA typing of fetal tissues could be used to establish the genotype of a putative CF homozygote and the couple offered a first trimester diagnosis in subsequent pregnancies. We have shown that there are no technical obstacles to this course of action.
There is, however, likely to be some error associated with the use of such fetal tissues in establishing the phase relationships of DNA markers. The largest component of the error arises from the fact that false positive diagnoses are possible using microvillar enzyme assay for the detection of fetal CF. The magnitude of the false positive rate is difficult to ascertain. At the Seventh International Congress on Human Genetics in September 1986, a collection of world wide experience of microvillar enzyme testing identified 10 false positives in 281 pregnancies (2.8%). 1 However, since most positive diagnoses are followed by termination of pregnancy, and since the validity of confirmation of diagnosis by examination of fetal meconium biochemistry cannot be rigorously tested, this is probably an underestimate. In support of this conclusion is the fact that the collected experience showed positive diagnoses being made in 29-2% of 1 in 4 risk pregnancies, significantly different from the 25% expected. This argues for a false positive rate of about 7%, if a false negative rate of 5% is assumed.
Even if the false positive rate in microvillar enzyme diagnoses were to be as high as 10%, there is merit in continuing to carry out DNA typing on fetal tissues. If fetal typing leads to erroneous establishment of phase relationships between DNA markers and the CF gene (because the fetus is a 'false positive'), only half of the subsequent diagnoses will be wrong, and only one quarter will lead to the birth of an affected child. Thus, the false positive rate will be reduced from 10% to 2-5%. The advantages to mothers of a first trimester prenatal diagnosis are so great that this is probably an acceptable error rate.
